Skip to main navigation Skip to search Skip to main content

Systemic adverse events following rituximab therapy in patients with Graves' disease

34 Citations (Scopus)

Abstract

Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.
Original languageEnglish
JournalJournal of Endocrinological Investigation
Volume34
Issue number7
Pages (from-to)e163-7
ISSN0391-4097
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Systemic adverse events following rituximab therapy in patients with Graves' disease'. Together they form a unique fingerprint.

Cite this